Cover Image

Toll-like receptor 4 antagonist and obesity associated kidney disease: Where should we go from here?

Saved in:

Bibliographic Details
Format:	Book
Published:	The Korean Society of Nephrology, 2015-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Where Do We Go From Here?
Published: (2016)

Precarious employment and occupational injuries in the digital age ‒ where should we go from here?
by: Helen Marucci-Wellman
Published: (2018)

Resistant Hypertension: Where are We Now and Where Do We Go from Here?
by: Pathan MK, et al.
Published: (2020)

Natural Products with Toll-Like Receptor 4 Antagonist Activity
by: Monica Molteni, et al.
Published: (2018)

Education in Interventional Pulmonology: How We Got Here and Where to Go from Here
by: Dylan Harrell, et al.
Published: (2024)

OMR At Crossroads; Where Do We Go From Here ?
by: Mangala Meti
Published: (2004)

The BENEFIT Trial: Where Do We Go from Here?
by: Bernard Pecoul, et al.
Published: (2016)

Vitamin D: where we should go
by: Costantino Romagnoli
Published: (2022)

Hospital Tax Exemption: Where Do We Go from Here?
Published: (2012)

The treatment of epilepsy in developing countries: where do we go from here?
by: Scott Robert A., et al.
Published: (2001)

The treatment of epilepsy in developing countries: where do we go from here?
by: Robert A. Scott, et al.

The future of patient experience: Five thoughts on where we must go from here
by: Jason Wolf
Published: (2019)

Where we are, where we are going
by: Teresa Bermejo-Vicedo, et al.
Published: (2020)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
by: Zhi-Mei Liu, et al.
Published: (2022)

Social Hormones and Human Behavior: What Do We Know and Where Do We Go from Here
by: Richard Paul Ebstein
Published: (2015)

Social Media and Artificial Intelligence: Critical Conversations and Where Do We Go from Here?
by: Julia Lynn Parra, et al.
Published: (2024)

Fall detection using accelerometer-based smartphones: Where do we go from here?
by: Tristan Stampfler, et al.
Published: (2022)

Going Forward, Going Back: Covid pandemic where to from here?
by: David S Briggs, et al.
Published: (2020)

Editor's Note to Volume 3 of the Journal of Communication Pedagogy: Where do we go from here?
by: Deanna D. Sellnow
Published: (2020)

COVID-19: Where Do We Go from Here? An Experience from Medical Students in India
by: Tanisha Kalra, et al.
Published: (2020)

Where do we go from here? A child rights-based response to COVID-19
by: Sharon Goldfeld, et al.
Published: (2020)

Where Are We Going?
by: Lloyd George, David, 1863-1945

How Effective Is Correctional Education, and Where Do We Go from Here? The Results of a Comprehensive Evaluation
by: Davis, Lois M.
Published: (2014)

Global and local perspectives on tobacco harm reduction: what are the issues and where do we go from here?
by: Sharon Cox, et al.
Published: (2018)

Toll-like Receptors
Published: (2020)

Toll-Like Receptors
by: Aycan Kundakcı, et al.
Published: (2012)

Health and Health Practice in Rural Australia: Where are We, Where to From Here?
by: Karen Francis
Published: (2005)

Pediatric Sepsis Research: Where Are We and Where Are We Going?
by: Letícia Massaud-Ribeiro, et al.
Published: (2022)

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going
by: Giovanni Boscarino, et al.
Published: (2023)

Colon Capsule Endoscopy: Where Are We and Where Are We Going
by: Yoo Min Han, et al.
Published: (2016)

FKBP Ligands-Where We Are and Where to Go?
by: Jürgen M. Kolos, et al.
Published: (2018)

Toll-Like Receptor 4 Signaling and Drug Addiction
by: Ruyan Wu, et al.
Published: (2020)

A Hundred Years of Diagnosing Superficial Fungal Infections: Where Do We Come From, Where Are We Now and Where Would We Like To Go?
by: Yvonne Gräser, et al.
Published: (2020)

Toll-like receptor 4 mutation mitigates gut microbiota-mediated hypertensive kidney injury
by: Suravi Majumder, et al.
Published: (2024)

AND US: WHERE ARE WE GOING?
by: Maria de Fátima Mantovani
Published: (2014)

Impacts of e-health on the outcomes of care in low-and middle-income countries: where do we go from here?
by: John D Piette, et al.
Published: (2012)

Correction to: Global and local perspectives on tobacco harm reduction: what are the issues and where do we go from here?
by: Sharon Cox, et al.
Published: (2018)

Effects of Toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet
by: Hye Sook Min, et al.
Published: (2014)

Toll-Like Receptor 4 (TLR4) and AMPK Relevance in Cardiovascular Disease
by: Haleh Vaez, et al.
Published: (2023)

Fetal myelomeningocele repair: where are we and where can we go?
by: Edward Araujo Júnior, et al.
Published: (2015)